Current process and future path for health economic assessment of pharmaceuticals in France

Mondher Toumi, Cécile Rémuzat, Emna El Hammi, Aurélie Millier, Samuel Aballéa, Christos Chouaid () and Bruno Falissard
Additional contact information
Mondher Toumi: Laboratoire de Santé Publique - Université de la Méditerranée - Aix-Marseille 2
Cécile Rémuzat: Creativ-Ceutical
Emna El Hammi: Evidenz
Aurélie Millier: Creativ-Ceutical
Samuel Aballéa: Creativ-Ceutical
Christos Chouaid: BCR - Biomécanique cellulaire et respiratoire - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 - CNRS - Centre National de la Recherche Scientifique
Bruno Falissard: UMR_S 669 - Troubles du comportement alimentaire de l'adolescent - UP11 - Université Paris-Sud - Paris 11 - UPD5 - Université Paris Descartes - Paris 5 - INSERM - Institut National de la Santé et de la Recherche Médicale

Post-Print from HAL

Abstract: The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.

Keywords: health economic assessment; CEESP; HAS; France; market access; cost-effectiveness (search for similar items in EconPapers)
Date: 2015
Note: View the original document on HAL open archive server: https://amu.hal.science/hal-01772997v1
References: View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Published in Journal of Market Access & Health Policy, 2015, 3 (1), pp.27902. ⟨10.3402/jmahp.v3.27902⟩

Downloads: (external link)
https://amu.hal.science/hal-01772997v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01772997

DOI: 10.3402/jmahp.v3.27902

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().